CSL Limited
CSLLY · OTC
Bulios Fair Price
$19.15
40.4% downside
Current Price
$32.13
According to Bulios Fair Price, CSLLY is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
About the company
CSL Limited is an Australian biotechnology company headquartered in Melbourne and one of the world’s leading developers and manufacturers of plasma-derived therapies, vaccines, and biotherapeutics. Founded in 1916 as a government laboratory, it now operates globally through its subsidiaries CSL Behring and CSL Seqirus. The company focuses on treating rare and serious conditions such as blood clotting disorders, immune deficiencies, respiratory diseases, and neurological disorders, while also being one of the largest producers of influenza vaccines worldwide. CSL emphasizes innovation, scientific research, and the advancement of biomedical technologies, with its products available in over 100 countries.
Sector
Healthcare
Industry
Biotechnology
CEO
Gordon Naylor DipCompSc
Employees
29,000
Headquarters
Melbourne